Why Praxis Precision Medicines, Inc.’s (PRAX) Stock Is Down 6.04%
As of Thursday, November 12, Praxis Precision Medicines, Inc.’s PRAX share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Tudor Pop
Cynthia McLaughlin
Cynthia McLaughlin
Michael Rose
| Share Statistics | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,397.5 | $203.5 | 77% |
|
| Shares Out (Mil) | 29.2 | 55.2 | 36% |
|
| Institutional Ownership | 99.8% | 93.3% | 94% |
|
| Float (Mil) | 24.1 | 40.4 | 31% |
|
| Beta | 2.84 | 1.05 | 97% |
|
| Avg Daily Volume (000s) | 670 | 569 | 62% |
|
| Price Change (52-week) |
58.7% | 38.8% | 91% |
|
| Growth | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (37.5%) | (10.7%) | 10% |
|
| EPS (5yr) | 35.2% | 15.4% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (56.9%) | (15.7%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 20 | 20 | 19 | |
| Current EPS | ($4.094) | ($13.468) | ($10.367) | |
| Month Ago EPS | ($4.243) | ($14.024) | ($9.502) | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($4.210) | ($13.935) | ($9.294) | |
| Year/Year Chg | 26.7% | (0.1%) | (147.7%) | |
| Financials | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($359) | ($44) | 4% |
|
| EPS (TTM) | ($12.757) | ($1.400) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($322) | ($35) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $212 | $-0 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $8,151 | $142 | 71% |
|
| Valuation | PRAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.67 | 1.96 | 88% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PRAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (42.1%) | (47.0%) | 13% |
|
| ROE | (44.8%) | (51.8%) | 16% |
|
| Liabilities to Assets | 4.0% | 29.6% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Praxis Precision Medicines, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors